Marlon Viloria, NP
Primary Care · Grayslake, ILNPI 1912514654
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 30 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by AstraZeneca at 26.0% of the total. Reporting peaked in 2021 at $907 and has fallen 73.2% since, to $243 in 2024.
Across 30 payments — averaging $51.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$403
- Novo Nordisk$355
- Amgen$231
- Harrow Eye, LLC$140
- Esperion Therapeutics, Inc.$139
- Corcept Therapeutics$100
- plus $181 from 4 others
What the payments were for
- Food & beverage$1,548100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 8 | $403 |
| Novo Nordisk | 5 | $355 |
| Amgen | 3 | $231 |
| Harrow Eye, LLC | 2 | $140 |
| Esperion Therapeutics, Inc. | 2 | $139 |
| Corcept Therapeutics | 1 | $100 |
| Lilly USA, LLC | 4 | $76 |
| Boehringer Ingelheim | 3 | $75 |
| Merck | 1 | $16 |
| GSK | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,548 in reported general payments places this provider in the 75th percentile of 150 primary care providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 91 | $108,943 |
| JanuviaSitagliptin Phosphate | 61 | $71,113 |
| FarxigaDapagliflozin Propanediol | 44 | $43,914 |
| EliquisApixaban | 46 | $35,527 |
| OzempicSemaglutide | 26 | $34,811 |
| RybelsusSemaglutide | 13 | $27,177 |
| TradjentaLinagliptin | 23 | $24,374 |
| Tresiba Flextouch U-200Insulin Degludec | 15 | $22,533 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $21,629 |
| XareltoRivaroxaban | 12 | $16,048 |
| MyrbetriqMirabegron | 11 | $14,311 |
| Ezetimibe | 178 | $7,969 |
| VascepaIcosapent Ethyl | 17 | $7,249 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 33 | $6,702 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $6,632 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $75 | $133,317114 claims |
| MerckJanuvia | $16 | $71,11361 claims |
| Novo NordiskOzempic, Rybelsus | $355 | $61,98839 claims |
| AstraZenecaFarxiga | $403 | $43,91444 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $14 | $28,26240 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 150 primary care providers in Illinois.
Other primary care in Grayslake
- Nicole LorangElk Grove Village$19K
- Allison LindstromChicago$15K
- Rachel ProkopfOak Park$13K
- Dawn ConwayChicago$11K
- Anne MaynardGlen Ellyn$9K
- Megan McLuckieHoffman Estates$9K
- Megan NiemiecNew Lenox$7K
- Ashley CarterChicago$7K
- Blake WoodsMetropolis$6K
- Jennifer VazquezChicago$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.